本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/11/12 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 12 日~2026 11 | 11 | 月 | 年 | 月 | 11 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 202,540股 | | | | | | | | 累计已回购股数占总股本比例 | 0.2185% | | | | | | | | 累计已回购金额 | 30,007,642.39元 | | | | | | | | 实际回购价格区间 | 145.59元/股~152.18元/股 | | | | ...

Core Viewpoint - The company, 热景生物 (Hotgen Biotech), has initiated its first share buyback through centralized bidding, indicating a strategic move to enhance shareholder value and confidence in its stock performance [1] Group 1: Share Buyback Details - The company repurchased a total of 202,500 shares, which represents 0.2185% of its total share capital [1] - The shares were bought at a minimum price of 145.59 CNY per share and a maximum price of 152.18 CNY per share [1] - The total amount spent on the buyback was 30.0076 million CNY, excluding transaction commissions and other fees [1]

Market Overview - The medical device sector experienced a slight increase of 0.04% on November 13, with Hotgen Biotech leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Top Gainers - Hotgen Biotech (688068) closed at 170.15, with a significant increase of 11.36% and a trading volume of 59,400 shares [1] - Jikang Development (600807) saw a rise of 9.92%, closing at 3.88 with a trading volume of 561,900 shares [1] - Hualan Biological Engineering (301093) increased by 8.35%, closing at 49.55 with a trading volume of 77,300 shares [1] - Other notable gainers include Baijun Medical (688198) up 6.14% and Wuzhou Medical (301234) up 4.43% [1] Top Losers - Yuanpeng Medical (300753) experienced a decline of 6.35%, closing at 28.76 with a trading volume of 150,800 shares [2] - Zhend Medical (603301) fell by 2.93%, closing at 88.04 with a trading volume of 82,900 shares [2] - Other significant declines include Kefu Medical (301087) down 2.73% and Canar Co. (301122) down 2.71% [2] Capital Flow - The medical device sector saw a net outflow of 937 million yuan from institutional investors, while retail investors contributed a net inflow of 722 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active [2] Individual Stock Capital Flow - Jikang Development had a net inflow of 47.75 million yuan from institutional investors, while retail investors showed a net outflow of 36.24 million yuan [3] - Hualan Biological Engineering recorded a net inflow of 44.30 million yuan from institutional investors, with retail investors experiencing a net outflow of 47.73 million yuan [3] - Other stocks like Sanxin Medical (300453) and Wuzhou Medical (301234) also showed varied capital flows, reflecting differing investor sentiments [3]

Core Insights - The stock price of Hotgen Biotech increased by 2.47% on November 13, reaching 156.56 CNY per share, with a total market capitalization of 14.514 billion CNY [1] Financial Performance - For the first nine months of 2025, Hotgen Biotech reported a revenue of 310 million CNY, a year-on-year decrease of 19.80%, and a net profit attributable to shareholders of -109 million CNY, a significant decline of 168.12% [2] - The company has distributed a total of 440 million CNY in dividends since its A-share listing, with 17.344 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average circulating shares per person decreased by 11.43% to 11,835 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease of 12.53% in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase of 50.00% in holdings by ICBC Frontier Medical Stock A [3] Stock Market Activity - Hotgen Biotech's stock has seen a year-to-date increase of 153.17%, with a recent five-day increase of 11.99%, but a decline of 11.71% over the past 20 days and 32.69% over the past 60 days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 4, where it recorded a net purchase of 47.8269 million CNY [1] Business Overview - Hotgen Biotech, established on June 23, 2005, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with a revenue composition of 70.87% from testing reagents, 19.79% from testing instruments, and 1.17% from biological raw materials [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in medical devices and in vitro diagnostics, and is associated with concepts such as Alzheimer's, innovative drugs, and antigen testing [2]

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Core Insights - The monkeypox concept sector saw a rise of 1.57%, ranking third among concept sectors, with 57 stocks increasing in value, including significant gains from companies like Bo Hui Innovation, which hit a 20% limit up, and others like He Fu China and Zhong Sheng Pharmaceutical reaching their daily limit up as well [1][2] Group 1: Market Performance - The monkeypox concept sector had a net inflow of 5.92 billion yuan, with 35 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top net inflow was from Zhong Sheng Pharmaceutical, which saw a net inflow of 4.36 billion yuan, followed by Fu Xiang Pharmaceutical and Bo Hui Innovation with net inflows of 1.28 billion yuan and 819.31 million yuan respectively [2][3] Group 2: Stock Performance - The stocks with the highest net inflow ratios included Bo Hui Innovation at 17.88%, Zhong Sheng Pharmaceutical at 14.67%, and Dong Fang Biological at 13.11% [3] - Notable stock performances included Bo Hui Innovation with a 20% increase, Zhong Sheng Pharmaceutical with a 10.02% increase, and He Fu China with a 10.02% increase as well [1][7]

Policy Developments - Jiangxi Province is promoting the development of brain-computer interface medical devices, emphasizing the need for regulatory compliance and collaboration among industry players to seize opportunities in emerging technologies [1] - The market for brain-computer interface medical devices is noted to have significant potential, with a strong development momentum in Jiangxi Province [1] Medical Device Approvals - In October, the National Medical Products Administration approved 204 medical device products, including 173 domestic Class III devices, 10 imported Class III devices, and 21 imported Class II devices [2] Pharmaceutical Logistics - The Shanghai Municipal Drug Administration encourages the development of modern pharmaceutical logistics, advocating for improved storage and management systems to enhance operational efficiency and reduce costs [3] Drug Approvals - Fangsheng Pharmaceutical announced that its Indobufen tablets received a drug registration certificate from the National Medical Products Administration, allowing for production [4] - Saito Bio's application for the chemical raw material drug Mometasone Furoate has been approved, indicating its use in treating asthma and skin conditions [5] - Tianyao Pharmaceutical received a drug registration certificate for Metoclopramide injection, which is used for treating nausea and vomiting [6] Capital Market Activities - Yingsi Intelligent submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for its AI-driven drug development initiatives [7][8] - Rejuve Bio plans to repurchase shares worth between 100 million and 200 million yuan to support employee stock ownership plans [9] Industry Developments - AstraZeneca's Baxdrostat demonstrated significant reductions in 24-hour average systolic blood pressure in treatment-resistant hypertension patients during the Bax24 Phase III trial, achieving a reduction of 14.0 mmHg compared to placebo [10][11] - The drug showed good overall tolerability and consistent safety profiles, with a notable percentage of patients achieving target blood pressure levels [11] - Maiwei Bio's IL-11 monoclonal antibody 9MW3811 received approval for Phase II clinical trials targeting pathological scars, marking it as the first IL-11 targeted drug to enter clinical trials for this indication [12] - Aiwei Technology's subsidiary obtained a medical institution practice license, enabling it to provide third-party medical testing services [13] - Anke Bio signed an exclusive agency framework agreement with Boshengji for the PA3-17 injection product, aimed at enhancing its product portfolio in the innovative drug market [14][15]

Group 1 - The outbreak of respiratory syncytial virus (RSV) in Tianjin has peaked earlier than expected, with flu activity rising in southern provinces and most northern provinces during the 44th week of 2025 [1] - The latest flu monitoring report from the National Disease Control indicates an increase in flu cases, highlighting the need for vigilance against RSV alongside influenza [4] Group 2 - In the A-share market, flu-related stocks are experiencing significant activity, with Aipeng Medical rising over 10%, and other companies like Panlong Pharmaceutical hitting the daily limit, indicating strong investor interest [2] - The detection rates for severe acute respiratory infections show that rhinovirus (10.6%), RSV (8.5%), and influenza virus (4.2%) are the top three pathogens, emphasizing the impact of RSV on public health [4]

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].